Literature DB >> 3205373

Transient paroxysmal dystonia in infancy.

L Angelini1, V Rumi, E Lamperti, N Nardocci.   

Abstract

A group of nine patients with paroxysmal non epileptic motor disorders, with onset in the first year of life, is presented. The characteristics of the attacks define them as paroxysmal dystonia. The progression of the symptoms showed a spontaneous remission in a short length of time (6-22 months) in most infants. In two of them the symptoms persist, showing, however, a progressive decrease. All the laboratory tests were normal. None of the subjects revealed neurological signs and psychomotor development was normal. A likely correlation between transient early-childhood paroxysmal dystonia and developmental processes is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3205373     DOI: 10.1055/s-2008-1052439

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  5 in total

Review 1.  Diagnosis and management of acute movement disorders.

Authors:  D Dressler; R Benecke
Journal:  J Neurol       Date:  2005-10-10       Impact factor: 4.849

2.  Transient paroxysmal dystonia in an infant possibly induced by cisapride.

Authors:  L Angelini; G Zorzi; V Rumi; N Nardocci; T Mennini
Journal:  Ital J Neurol Sci       Date:  1996-04

Review 3.  Episodic movement disorders: from phenotype to genotype and back.

Authors:  Knut Brockmann
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

Review 4.  Update on pediatric dystonias: etiology, epidemiology, and management.

Authors:  Emilio Fernández-Alvarez; Nardo Nardocci
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-04-11

Review 5.  Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.

Authors:  Giacomo Garone; Alessandro Capuano; Lorena Travaglini; Federica Graziola; Fabrizia Stregapede; Ginevra Zanni; Federico Vigevano; Enrico Bertini; Francesco Nicita
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.